HIF prolyl-hydroxylase inhibitor

HIF prolyl-hydroxylase inhibitors are members of a class of new drugs that act on the hypoxia-inducible factor (HIF) pathway. They are being investigated for treatment of anemia, chronic kidney disease[1], cancer[2], and for their effects on heart tissue[3] and others.[4]

References

  1. ^ http://www.fasebj.org/cgi/content/full/17/9/1186 "Activation of the hypoxia-inducible factor-pathway and stimulation of angiogenesis by application of prolyl hydroxylase inhibitors" 2003
  2. ^ http://www.maedica.ro/articole/nr2/10_HIF-PROLYL.pdf "HIF-PROLYL hydroxylase inhibitors: From basic science to clinical trials" 2006
  3. ^ http://atvb.ahajournals.org/cgi/content/abstract/27/12/2548 "A Novel Class of Prolyl Hydroxylase Inhibitors Induces Angiogenesis and Exerts Organ Protection Against Ischemia" 2007
  4. ^ http://www.drugs.com/clinical_trials/fibrogen-reports-new-research-development-hif-prolyl-hydroxylase-inhibitors-related-endothelial-3230.html "FibroGen Reports New Research on Development of HIF Prolyl Hydroxylase Inhibitors Related to Endothelial Progenitor Cells, Anti-Inflammation, Cytoprotection and Erythropoiesis" 2008

See also